Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 2
1970 2
1971 2
1972 2
1974 2
1976 3
1977 2
1978 1
1979 4
1980 3
1981 2
1982 2
1983 1
1984 2
1985 4
1986 19
1987 4
1988 4
1989 7
1990 34
1991 3
1992 5
1993 16
1994 8
1995 9
1996 19
1997 17
1998 29
1999 30
2000 32
2001 51
2002 38
2003 44
2004 47
2005 49
2006 48
2007 44
2008 51
2009 39
2010 36
2011 33
2012 33
2013 37
2014 46
2015 47
2016 55
2017 41
2018 50
2019 60
2020 56
2021 70
2022 55
2023 55
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

1,293 results

Results by year

Filters applied: . Clear all
Page 1
Trimetazidine in cardiovascular medicine.
Marzilli M, Vinereanu D, Lopaschuk G, Chen Y, Dalal JJ, Danchin N, Etriby E, Ferrari R, Gowdak LH, Lopatin Y, Milicic D, Parkhomenko A, Pinto F, Ponikowski P, Seferovic P, Rosano GMC. Marzilli M, et al. Int J Cardiol. 2019 Oct 15;293:39-44. doi: 10.1016/j.ijcard.2019.05.063. Epub 2019 May 24. Int J Cardiol. 2019. PMID: 31178223 Review.
For these reasons, several studies have explored the potential benefits of trimetazidine (TMZ), an inhibitor of free fatty acids oxidation that shifts cardiac and muscle metabolism to glucose utilization. ...
For these reasons, several studies have explored the potential benefits of trimetazidine (TMZ), an inhibitor of free fatty acids oxid …
WITHDRAWN: Trimetazidine for stable angina.
Ciapponi A, Pizarro R, Harrison J. Ciapponi A, et al. Cochrane Database Syst Rev. 2017 Mar 20;3(3):CD003614. doi: 10.1002/14651858.CD003614.pub3. Cochrane Database Syst Rev. 2017. PMID: 28319269 Free PMC article. Review.
Four small trials (263 patients) compared trimetazidine against other anti-anginal agents. One favoured trimetazidine over nitrates. ...Trimetazidine may result in fewer dropouts due to adverse events. Large, long term trials comparing trimetazidine wi …
Four small trials (263 patients) compared trimetazidine against other anti-anginal agents. One favoured trimetazidine over nit …
Trimetazidine Use in Parkinson's Disease: Is It a Resolved Problem?
Pintér D, Bereczki D, Ajtay A, Oberfrank F, Janszky J, Kovács N. Pintér D, et al. eNeuro. 2021 May 19;8(3):ENEURO.0452-20.2021. doi: 10.1523/ENEURO.0452-20.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 33863783 Free PMC article. Review.
Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EMA) recommended avoiding the use of this drug in Parkinson's disease (PD). ...
Trimetazidine (TMZ), an antianginal drug, can worsen the symptoms of movement disorders, therefore, the European Medicines Agency (EM …
Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury.
Farzaei MH, Ramezani-Aliakbari F, Ramezani-Aliakbari M, Zarei M, Komaki A, Shahidi S, Sarihi A, Salehi I. Farzaei MH, et al. Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1633-1646. doi: 10.1007/s00210-023-02469-7. Epub 2023 Mar 27. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36971866 Review.
Cardiovascular miRNAs, specifically miR-21, and probably miR-24 and miR-126 have protective effects on myocardial I/R injury. Trimetazidine (TMZ) is a new class of metabolic agents with an anti-ischemic activity. ...
Cardiovascular miRNAs, specifically miR-21, and probably miR-24 and miR-126 have protective effects on myocardial I/R injury. Trimetazidi …
Trimetazidine an emerging paradigm in renal therapeutics: Preclinical and clinical insights.
Gupta K, Pandey S, Bagang N, Mehra K, Singh G. Gupta K, et al. Eur J Pharmacol. 2021 Dec 15;913:174624. doi: 10.1016/j.ejphar.2021.174624. Epub 2021 Nov 10. Eur J Pharmacol. 2021. PMID: 34774496 Review.
Trimetazidine (TMZ) is a well-known anti-ischemic agent used for the treatment of angina pectoris. ...
Trimetazidine (TMZ) is a well-known anti-ischemic agent used for the treatment of angina pectoris. ...
Trimetazidine for stable angina.
Ciapponi A, Pizarro R, Harrison J. Ciapponi A, et al. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003614. doi: 10.1002/14651858.CD003614.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2017 Mar 20;3:CD003614. doi: 10.1002/14651858.CD003614.pub3. PMID: 16235330 Updated. Review.
Four small trials (263 patients) compared trimetazidine against other anti-anginal agents. One favoured trimetazidine over nitrates. ...Trimetazidine may result in fewer dropouts due to adverse events. Large, long term trials comparing trimetazidine wi …
Four small trials (263 patients) compared trimetazidine against other anti-anginal agents. One favoured trimetazidine over nit …
Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.
van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA, Allaart CP, Nederveen AJ, van Rossum AC, Bakermans AJ, Handoko ML. van de Bovenkamp AA, et al. ESC Heart Fail. 2023 Oct;10(5):2998-3010. doi: 10.1002/ehf2.14418. Epub 2023 Aug 2. ESC Heart Fail. 2023. PMID: 37530098 Free PMC article. Clinical Trial.
Myocardial phosphocreatine/adenosine triphosphate in the trimetazidine arm was similar to placebo (1.08 [0.76, 1.76] vs. 1.30 [0.95, 1.86], P = 0.08). ...CONCLUSIONS: Trimetazidine did not improve myocardial energy homeostasis and did not improve exercise haemodynam …
Myocardial phosphocreatine/adenosine triphosphate in the trimetazidine arm was similar to placebo (1.08 [0.76, 1.76] vs. 1.30 [0.95, …
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1(G93A) mice.
Scaricamazza S, Salvatori I, Amadio S, Nesci V, Torcinaro A, Giacovazzo G, Primiano A, Gloriani M, Candelise N, Pieroni L, Loeffler JP, Renè F, Quessada C, Tefera TW, Wang H, Steyn FJ, Ngo ST, Dobrowolny G, Lepore E, Urbani A, Musarò A, Volonté C, Ferraro E, Coccurello R, Valle C, Ferri A. Scaricamazza S, et al. Br J Pharmacol. 2022 Apr;179(8):1732-1752. doi: 10.1111/bph.15738. Epub 2022 Jan 13. Br J Pharmacol. 2022. PMID: 34783031 Free PMC article.
We therefore evaluated the therapeutic potential of the multi-target drug used to treatment of coronary artery disease, trimetazidine, in SOD1(G93A) mice. EXPERIMENTAL APPROACH: As a metabolic modulator, trimetazidine improves glucose metabolism. ...We orally treate …
We therefore evaluated the therapeutic potential of the multi-target drug used to treatment of coronary artery disease, trimetazidine …
Trimetazidine in Practice: Review of the Clinical and Experimental Evidence.
Dézsi CA. Dézsi CA. Am J Ther. 2016 May-Jun;23(3):e871-9. doi: 10.1097/MJT.0000000000000180. Am J Ther. 2016. PMID: 25756467 Free PMC article. Review.
All of the following traditional agents for the management of stable angina pectoris include the symptomatic treatment with heart rate-lowering agents such as beta-blockers or non-dihydropyridine Ca-channel blockers, or ivabradine-the first selective sinus node If channel inhibit …
All of the following traditional agents for the management of stable angina pectoris include the symptomatic treatment with heart rate-lower …
1,293 results

Searches related to "trimetazidine"